Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.
about
The search for novel analgesics: targets and mechanismsFunctional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonistsOpioid receptors: toward separation of analgesic from undesirable effectsStructural and functional interactions between six-transmembrane μ-opioid receptors and β2-adrenoreceptors modulate opioid signalingBroad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene.Opiate pharmacology and relief of pain.Pharmacologic characterization in the rat of a potent analgesic lacking respiratory depression, IBNtxA.Synthesis and evaluation of aryl-naloxamide opiate analgesics targeting truncated exon 11-associated μ opioid receptor (MOR-1) splice variants.Differential expressions of the alternatively spliced variant mRNAs of the µ opioid receptor gene, OPRM1, in brain regions of four inbred mouse strainsReview of preclinical studies on treatment of mucositis and associated painRevolution in GPCR signalling: opioid receptor heteromers as novel therapeutic targets: IUPHAR review 10.Opioids and their receptors: Are we there yet?Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs.The N-terminally truncated µ3 and µ3-like opioid receptors are transcribed from a novel promoter upstream of exon 2 in the human OPRM1 gene.Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction.Mu Opioid Splice Variant MOR-1K Contributes to the Development of Opioid-Induced Hyperalgesia.Synthesis and pharmacology of halogenated δ-opioid-selective [d-Ala(2)]deltorphin II peptide analoguesDifferential Regulation of 6- and 7-Transmembrane Helix Variants of μ-Opioid Receptor in Response to Morphine StimulationGenomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons.Mediation of opioid analgesia by a truncated 6-transmembrane GPCR.Splice variation of the mu-opioid receptor and its effect on the action of opioids.Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behaviorTruncated mu opioid GPCR variant involvement in opioid-dependent and opioid-independent pain modulatory systems within the CNS.Sandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully-deprotected peptides: studies on the endogenous opioid peptide α-neoendorphin.Stabilization of the μ-opioid receptor by truncated single transmembrane splice variants through a chaperone-like action.Mu opioids and their receptors: evolution of a concept.Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management.Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo.Novel 6β-acylaminomorphinans with analgesic activity.Morphine regulates expression of μ-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the μ-opioid receptor (OPRM1) gene via miR-103/miR-107.Isolating and characterizing three alternatively spliced mu opioid receptor variants: mMOR-1A, mMOR-1O, and mMOR-1P.Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine.Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.The roles played by highly truncated splice variants of G protein-coupled receptors.μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.Supraspinal inhibitory effects of chimeric peptide MCRT on gastrointestinal motility in mice.Mild, Pd-catalyzed stannylation of radioiodination targets.Breaking barriers to novel analgesic drug development.
P2860
Q24288817-B972E309-88CB-470F-AD49-36D139DC41AEQ26852027-329AAB33-D728-47ED-8D24-7C72FCE4F0BAQ27002925-7CBE68BF-B8C3-4A2C-80B3-E0431BEBCB56Q27303730-EC0B9BA7-334D-4350-AA72-A16E5FAFF4B6Q30631761-090103ED-BF3F-4624-992B-57963172BD30Q33650564-1D66D30D-831B-4664-AFBB-B47A23385993Q34125112-049D53D3-9D77-45B2-B1B4-D7736C95ACF7Q34284204-B55048CB-B354-4889-AECD-5A0B61CE70EBQ34400986-19D1A268-BE2A-43D7-99E6-A8E70C090CBBQ34421916-F1981779-F480-4BD9-BA43-00ECB31CB0E2Q34424009-45ADFFBF-1C0F-4C69-B481-4549B10378F6Q34437456-BB391CAE-B338-48A6-818B-402756DACAE7Q34538336-1608483C-4015-4A33-8E75-A569A4B7FF24Q34926300-3ECDCE2F-EE83-4E12-A848-FEFAD5F833E8Q34948489-1AC76473-903A-4D17-BE90-9539F74A76C8Q35007339-BAD9638C-5879-4786-8F96-B45887B7118CQ35684498-EA87A942-9715-4F5A-B370-C08D8EB5A0FAQ35745117-C62B1999-23DD-4914-9BB1-AF8E87B5F045Q35756505-73069300-B0F5-45B8-857C-23EEC78E1FA0Q35837099-03EF9D0B-C8FD-404C-929B-F3FA0B75AB8BQ35887385-F8297148-FD26-4A8A-9C3E-9B542B3827F7Q36040286-7F6B997E-C4F1-4B20-9320-E8FA4B86A330Q36195269-5FF8A6EE-9973-4245-BF70-8E33A800744EQ36296493-BA0BB500-9A75-4B94-AEA9-6A8E0966668FQ36770675-743F3FA0-B257-49C1-BF33-D33D6F8F08FDQ37049634-E196F490-4115-41FE-9E29-C37028E8D17BQ37175164-B3A0D916-0912-46CF-A2E7-4F75CEB61E21Q37236111-54972D97-664A-4E27-AE15-F4C356C9D427Q37258385-1AFFE4B5-D7BD-4B2D-AE15-15A7A522E420Q37308492-59310BEA-7ECA-4A58-8152-349383008757Q37340566-4129AE06-B13F-49BB-B0F0-F93E5283A60FQ37553516-6D001356-3486-44E8-B716-7B57EFACAA82Q37588798-B50329BF-130C-4890-A4A0-2D7D187A2CCAQ37730688-BEE7ECF5-114D-4682-85A4-E4183FE59524Q37739812-E0F67E45-562A-4F99-B162-59B3E11DFDE2Q38039520-5CC86630-1EA2-4047-82B9-66AB2E269F9BQ38285112-44504B46-AFF6-4F57-A1D8-C82F8DB27D22Q39154155-6E3D64ED-3DF4-401F-955A-23138ECC48BCQ39233552-91C74A43-178B-4E54-81D5-0BA836A168C6Q39360773-73899BCF-DF64-404A-B8F4-EF72897849F3
P2860
Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Truncated G protein-coupled mu ...... algesics lacking side effects.
@ast
Truncated G protein-coupled mu ...... algesics lacking side effects.
@en
Truncated G protein-coupled mu ...... algesics lacking side effects.
@nl
type
label
Truncated G protein-coupled mu ...... algesics lacking side effects.
@ast
Truncated G protein-coupled mu ...... algesics lacking side effects.
@en
Truncated G protein-coupled mu ...... algesics lacking side effects.
@nl
prefLabel
Truncated G protein-coupled mu ...... algesics lacking side effects.
@ast
Truncated G protein-coupled mu ...... algesics lacking side effects.
@en
Truncated G protein-coupled mu ...... algesics lacking side effects.
@nl
P2093
P2860
P356
P1476
Truncated G protein-coupled mu ...... algesics lacking side effects.
@en
P2093
Gavril W Pasternak
John Pintar
Lisa Polikar
Maxim Burgman
Michael Ansonoff
Susruta Majumdar
Valerie Le Rouzic
Ying-Xian Pan
P2860
P304
19778-19783
P356
10.1073/PNAS.1115231108
P407
P577
2011-11-21T00:00:00Z